Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NCT ID: NCT05327127

Last Updated: 2025-06-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

228 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-14

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NASH

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

K-001

K-877-ER and CSG452 Once daily (QD)

Group Type EXPERIMENTAL

K-877-ER

Intervention Type DRUG

K-877-ER tablet

CSG452

Intervention Type DRUG

CSG452 tablet

K-877-ER

K-877-ER and CSG452 Placebo QD

Group Type EXPERIMENTAL

K-877-ER

Intervention Type DRUG

K-877-ER tablet

Placebo

Intervention Type DRUG

Placebo tablet

CSG452

CSG452 and K-877-ER Placebo QD

Group Type EXPERIMENTAL

CSG452

Intervention Type DRUG

CSG452 tablet

Placebo

Intervention Type DRUG

Placebo tablet

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

K-877-ER

K-877-ER tablet

Intervention Type DRUG

CSG452

CSG452 tablet

Intervention Type DRUG

Placebo

Placebo tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to understand and comply with study procedures and give written informed consent
* Age ≥18 years
* NAS ≥4 with a score of at least 1 in each component of the NAS (steatosis, lobular inflammation, and ballooning) at Visit 2 liver biopsy, or a historical liver biopsy performed within 24 weeks of randomization
* Fibrosis stage of 1 or greater and below 4 on NASH CRN (Clinical Research Network) fibrosis staging system at Visit 2 liver biopsy, or a historical liver biopsy performed within 24 weeks of randomization

Exclusion Criteria

* Participation in another clinical trial involving an investigational agent within 30 days prior to signing the Informed Consent Form (ICF) for this study
* Ongoing or recent consumption of Greater than moderate amounts of alcohol as defined in clinical study protocol
* Evidence of other forms of chronic liver disease as defined in clinical study protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kowa Research Institute, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shona Pendse, MD, MMSc

Role: STUDY_CHAIR

Kowa Research Institute, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Adobe Clinical Research, LLC

Tucson, Arizona, United States

Site Status

Arizona Liver Health

Tucson, Arizona, United States

Site Status

Arcare Center for Clinical Research

Little Rock, Arkansas, United States

Site Status

Clinical Trials Research

Lincoln, California, United States

Site Status

United Clinical Research Institute

Los Alamitos, California, United States

Site Status

Velocity Clinical Research

Los Angeles, California, United States

Site Status

Alliance Clinical Research

Poway, California, United States

Site Status

Nature Coast Clinical Research, LLC

Inverness, Florida, United States

Site Status

ENCORE Borland Groover Clinical Research

Jacksonville, Florida, United States

Site Status

Miami Clinical Research

Miami, Florida, United States

Site Status

Ocala GI Research

Ocala, Florida, United States

Site Status

Sensible Healthcare Clinical Research, LLC

Ocoee, Florida, United States

Site Status

Centricity Research

Columbus, Georgia, United States

Site Status

Gastrointestinal Specialists of Georgia, PC

Marietta, Georgia, United States

Site Status

Iowa Digestive Disease Center

Clive, Iowa, United States

Site Status

Tandem Clinical Research, LLC

Marrero, Louisiana, United States

Site Status

Mid-Atlantic GI Research, LLC

Greenbelt, Maryland, United States

Site Status

Boston Medical Center Boston University Chobanian & Avedisian School of Medicine

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

GI Alliance Research

Flowood, Mississippi, United States

Site Status

GI Associates Research, LLC

Columbia, Missouri, United States

Site Status

Jefferson City Medical Group

Jefferson City, Missouri, United States

Site Status

Lucas Research, Inc.

Morehead City, North Carolina, United States

Site Status

DSI Research Northridge, LLC

Dayton, Ohio, United States

Site Status

Penn State Health/Penn State College of Medicine

Hershey, Pennsylvania, United States

Site Status

GI Alliance Research

Cedar Park, Texas, United States

Site Status

GI Alliance Research

Dallas, Texas, United States

Site Status

GI Alliance Research

Garland, Texas, United States

Site Status

GLRI McAllen Research

Pharr, Texas, United States

Site Status

Northeast Clinical Rsearch of San Antonio

San Antonio, Texas, United States

Site Status

Endeavor Clinical Trials

San Antonio, Texas, United States

Site Status

Impact Research Institute

Waco, Texas, United States

Site Status

Digestive Health Research of Central Texas, LLC

Waco, Texas, United States

Site Status

North Richmond Health Research

Richmond, Virginia, United States

Site Status

GI Select Health Research

Richmond, Virginia, United States

Site Status

Centricity

Suffolk, Virginia, United States

Site Status

Liver Institute Northwest

Seattle, Washington, United States

Site Status

Hospital Italiano de Buenos Aires

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Site Status

CINME - Centro De Investigaciones Metabolicas

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Hospital Italiano de La Plata

La Plata, Buenos Aires, Argentina

Site Status

Instituto de Investigaciones Clinicas de Mar del Plata

Mar del Plata, Buenos Aires, Argentina

Site Status

Hospital Universitario Austra

Pilar, Buenos Aires, Argentina

Site Status

Hospital Provincial del Centenario

Santa Fe, Rosario, Argentina

Site Status

Clínica de Endocrinologia e Metabologia Ltda

Brasília, Brasilia DF, Brazil

Site Status

Hospital Alianca Rede D 'Or

Salvador, Estado de Bahia, Brazil

Site Status

Hospital Universitário João de Barros Barreto

Belém, Pará, Brazil

Site Status

Hospital de Clinicas de Porto Alegre

Porto Alegre, Porto Alegre RS, Brazil

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

Ecogene-21

Chicoutimi, Quebec, Canada

Site Status

McGill University Health Centre

Montreal, Quebec, Canada

Site Status

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

Site Status

Fujita Health University Hospital

Toyoake, Aichi-ken, Japan

Site Status

Ehime University Hospital

Tōon, Ehime, Japan

Site Status

Fukui-ken Saiseikai Hospital

Fukui-shi, Fukui, Japan

Site Status

Ogaki Municipal Hospital

Ōgaki, Gifu, Japan

Site Status

NHO Takasaki General Medical Center

Takasaki Shi, Gumna, Japan

Site Status

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Hiroshima, Hiroshima, Japan

Site Status

NHO Kure Medical Center and Chugoku Cancer Center

Kure Shi, Hiroshima, Japan

Site Status

Asahikawa Medical University Hospital

Asahikawa, Hokkaido, Japan

Site Status

JCHO Hokkaido Hospital

Sapporo, Hokkaido, Japan

Site Status

Kanazawa University Hospital

Kanazawa, Ishikawa-ken, Japan

Site Status

SHIN-YURIGAOKA General Hospital

Kawasaki, Kanagawa, Japan

Site Status

St. Marianna University School of Medicine

Kawasaki, Kanagawa, Japan

Site Status

Yokohama City University Hospital

Yokohama, Kanagawa, Japan

Site Status

Tohoku Rosai Hospital

Sendai, Miyagi, Japan

Site Status

Shinshu University Hospital

Matsumoto Shi, Nagano, Japan

Site Status

Nagano municipal Hospital

Nagano, Nagano, Japan

Site Status

Saiseikai Niigata Hospital

Niigata, Niigata, Japan

Site Status

Kawasaki Medical School General Medical Center

Okayama, Okayama-ken, Japan

Site Status

Saga University Hospital

Saga, Saga-ken, Japan

Site Status

Japanese Red Cross Musashino Hospital

Musashino, Tokyo, Japan

Site Status

Nippon Medical School Hospital

Bunkyō City, Toyko, Japan

Site Status

Oita Cardiovascular Hospital

Ōita, , Japan

Site Status

Hospital Universitario Marques de Valdecilla

Santander, Cantabria, Spain

Site Status

Complejo Hospitalario Universitario A Coruna

A Coruña, , Spain

Site Status

Hospital General Universitario Gregorio Maranon

Madrid, , Spain

Site Status

Hospital Universitario Puerta De Hierro

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Brazil Canada Japan Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K-001-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.